"For many people with type 2 diabetes, it is a struggle to achieve both A1C control and weight loss, since obesity has historically been harder to treat for those with type 2 diabetes," Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, said in a press release
It depends on how you respond to it, how well you can handle it, and your specific weight loss goals
Orforglipron (Foundayo) New for 2026 The newest addition to the metabolic toolkit, this is a non-peptide oral medication recently approved by the FDA
This dual distribution supports both localized tissue repair and systemic regenerative signaling
It plays a crucial role in transporting long-chain fatty acids into the mitochondria, the powerhouse of your cells
When she asked her doctor about semaglutide, the blockbuster weight loss drug sold as Ozempic and Wegovy, she wasnt an obvious candidate for it